3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
42
Leukemia
35
Lymphoma
19
Myelodysplastic Syndromes
15
Precursor Cell Lymphoblastic Leukemia-Lymphoma
14
Lymphoma, Non-Hodgkin
13
Hodgkin Disease
13
Leukemia, Myeloid, Acute
12
Multiple Myeloma
11
Myeloproliferative Disorders
9
Recurrence
8
Lymphoma, T-Cell, Peripheral
8
Lymphoma, Mantle-Cell
7
Lymphoma, Large B-Cell, Diffuse
7
Lymphoma, B-Cell, Marginal Zone
7
Burkitt Lymphoma
7
Lymphoma, T-Cell, Cutaneous
6
Lymphoma, Large-Cell, Immunoblastic
6
Lymphoma, Follicular
6
Hematologic Neoplasms
6
Congenital Abnormalities
6
Waldenstrom Macroglobulinemia
5
Sezary Syndrome
5
Primary Myelofibrosis
5
Neoplasms, Plasma Cell
5
Mycosis Fungoides
5
Leukemia, Myeloid, Chronic-Phase
5
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
5
Anemia, Aplastic
5
Myelodysplastic-Myeloproliferative Diseases
4
Interventions
aldesleukin
9
Interleukin-2
9
Nivolumab
7
fludarabine phosphate
6
Dacarbazine
6
Cyclophosphamide
6
fludarabine
5
Temozolomide
4
Ipilimumab
4
Fluorouracil
4
montanide ISA 51
3
Surveys and Questionnaires
3
Semaxinib
3
Radiotherapy
3
Radiation
3
Mohs Surgery
3
Educational Status
3
Cisplatin
3
Allovectin-7
3
zanolimumab
2
talabostat
2
sonidegib
2
poly ICLC
2
binimetinib
2
Whole-Body Irradiation
2
Vinblastine
2
Vemurafenib
2
Tacrolimus
2
Tablets
2
Surgical Procedures, Operative
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Skin Neoplasms
×
Alemtuzumab
×
Clear all
NCT06705608
2024-11-26
MS; FTY720
University of British Columbia
Completed
4,000 enrolled